Newsroom

The latest, from us. Publications, press releases, and more.

—Business

30 | 04 | 2024

Announcing Exclusive Partnership with Visionix Italy

Announcing Exclusive Partnership with Visionix Italy Focused at Enhancing Eye Care Solutions in Italy

08 | 04 | 2024

In the Press: on MedTech Outlook

In the Press: on MedTech Outlook Espansione Group Named TOP Vision Care Solutions Provider in Europe

26 | 02 | 2024

Announcing Exclusive Partnership with Rodenstock Norge AS

Announcing Exclusive Partnership with Rodenstock Norge AS Aimed at Elevating Eye Care Professionals in Norway

03 | 05 | 2023

Announcing Exclusive Partnership with Topcon Healthcare SEA

Announcing Exclusive Partnership Between Topcon Healthcare SEA and Espansione Group aimed at Driving Disruptive Innovation in Eye Care and Beyond in South-East Asia

24 | 02 | 2023

Announcing Exclusive Partnership with Topcon Healthcare Great Britain & Ireland

Announcing Exclusive Partnership Between Topcon Great Britain & Ireland and Espansione Group Aimed at Elevating Eye Care Innovation in Ocular Surface & Beyond

01 | 02 | 2023

Espansione Group Announces the Appointment of a New Management Team

Espansione Group Announces the Appointment of a New Management Team Aimed at Granting Continuity in Cross-generational Leadership Exchange

18 | 01 | 2023

Espansione Group Announces Exclusive Partnership with Essilor Instruments

Announcing Exclusive Partnership Between Essilor Instruments and Espansione Group Aimed at Offering Innovative Solutions in the USA and Canada

16 | 01 | 2023

In the Press: Harvard Business Review

Espansione Group's Story Gets Featured on Harvard Business Review, Talking Strategy, Cross-generational Exchange and the New Leadership's Future Vision

13 | 03 | 2023

In the Press: Forbes

Espansione Group's Leadership Amongst Forbes' 30 Under 30, Interview on Business Growth and Industry Outlook

—Clinical

21 | 09 | 2024

LightWave I Clinical Trial Confirms Safety and Short-term Efficacy of Light Modulation® LLLT (PBM) on eye-light® for dAMD

6-Month Follow-up Study Demonstrates Safety and Tolerability Alongside Significant BCVA Improvement and Drusen Volume Reduction

17 | 09 | 2024

Espansione Group Announces MeiboMetrics: an Innovative, AI-powered Algorithm for Meibomian Gland Segmentation & Quantitative Measurement

Launching in 2025 on me-check® Pro and Other Platforms, MeiboMetrics Will Unlock Opportunities in Data-driven Patient Management.

13 | 09 | 2024

New Preliminary Results Highlight LM® LLLT's Effectiveness in Managing DED and IOP in Glaucomatous Patients

Photobiomodulation Emerges as a Promising Tool to Manage Drug-induced Iatrogenic Dry Eye and to Coadiuvate IOP Management

11 | 09 | 2024

Espansione Group Announces Topline Results from Refractive Surgery Study and Launch of Premium IOL Protocol Development

LM® LLLT Proves Itself as Valuable Tool for Surgeons Looking to Stabilize
the Tear Film Pre-/Post-surgery and Elevate Premium IOL Implants

03 | 06 | 2024

eye-light® Device Receives CE (MDR) Mark for Treating Dry AMD and Anterior Segment Pathologies

Unlocking New Horizons with Photobiomodulation from the Front to the Back of the Eye

17 | 05 | 2024

Announcing Clinical Trial Aimed at Studying LM® LLLT and its Biochemical Regulation Effects on the Ocular Microbiome

Exploring the Frontier of Photobiomodulation Therapy to Enhance Ocular Health with Aston University

31 | 10 | 2023

Elevating Cataract & Refractive Surgery

Espansione Group, a pioneer in the medtech industry and an advocate for science-driven innovation, proudly shares the results of a recently published double-blinded, randomized and controlled investigation focusing on the prevention of surgery-induced dry eye in cataract patients.

05 | 10 | 2023

LightWave I - Case Reports from a Disruptive Multi-centric Clinical Trial Employing PBM Technology in Dry AMD

Espansione Group, a pioneer in the medtech industry and an advocate for science-driven innovation, proudly unveils the first preliminary results of its recent multicentric, randomized controlled investigation: LightWave I.

17 | 05 | 2023

Announcing Clinical Trial Aimed at Demonstrating Efficacy of Light Therapy as Routine in Refractive Surgery-related Dry Eye Disease

We are thrilled to announce today the kick-off of the monocentric, randomized, simple bling, controlled clinical study on the efficiency of a combined Treatment With Pulsed Light and Photobiomodulation Before Laser Refractive Surgery (TEBELID).

11 | 05 | 2023

LM® LLLT + OPE® IPL: Consistently Effective Together.

Light Modulation® LLLT technology has recently been studied in a piece of research in combination therapy with OPE® IPL tech. The retrospective, monocentric study carried out in the Ophthalmology Department at Brest University Hospital, evaluates the efficacy and tolerance of intense pulsed light (IPL) therapy with low‐level light therapy (LLLT), our patented photo-biomodulation technology, in the treatment of meibomian gland dysfunction (MGD).

05 | 05 | 2023

LM® LLLT + OPE® IPL: Powerful Synergy.

We’re proud to announce our Light Modulation® LLLT technology has recently been studied in a piece of research in combination therapy with OPE® IPL tech. The randomized, controlled, blinded study evaluates the efficacy of intense pulsed light (IPL) therapy with low‐level light therapy (LLLT) in the treatment of meibomian gland dysfunction (MGD) and evaporative dry eye (EDE) compared to a control group.

28 | 04 | 2023

Announcing LightWave II: LM® LLLT for Dry AMD Global Research Study

LightWave II is the second, global, multi-centric research effort to study patented photobiomodulation technology LM® LLLT for dry AMD management.
LightWave II is being announced today with the aim of strengthening the already existing body of research around PBM in AMD management.

30 | 11 | 2022

Our scientific discoveries and our entrepreneurial successes have been featured in the best outlets worldwide.

Get Started Now

Get in touch to find out how you can benefit from the Espansione Ecosystem of Technologies and Solutions.

> Get Started